REGN Regeneron Pharmaceuticals, Inc.

455.17
-0.53  -0%
Previous Close 455.70
Open 456.70
Price To book 9.89
Market Cap 48.05B
Shares 105,571,000
Volume 475,520
Short Ratio 2.82
Av. Daily Volume 916,644

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial to be initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 data due 1Q 2018.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 2 trial to commence 1H 2017.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
REGN2810
Basal cell carcinoma
Phase 3 trial to be initiated using only lower doses from Phase 2/3 trial.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data due 2H 2017.
REGN2222
Respiratory syncytial virus (RSV)
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 continues to enroll - May 2017.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 data due 4Q 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3 trial commenced 4Q 2016.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis.
Fasinumab
Osteoarthritis and chronic low back pain
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 2 trial to commence 1H 2017.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
REGN2810
Basal cell carcinoma
Phase 2 enrollment completed 4Q 2016. Data due 2H 2017.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data due 2H 2017.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2H 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data released May 4, 2017.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis

Latest News

  1. Which Biotechs Benefit Most Under Trump's Tax Reform Vision?
  2. Are Regeneron, Sanofi Treading On Pfizer In Eczema?
  3. Biotech And Pharma Industry And Stock News
  4. Regeneron Presents Positive Phase II Data on HoFH Candidate
  5. The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
  6. Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH
  7. Theravance/Mylan Presents Phase III Data on COPD Candidate
  8. Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
  9. Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with Relapsing Multiple Sclerosis
  10. Wide-Moat Roche Is Undervalued
  11. Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
  12. ​Sanofi Genzyme takes on world’s top-selling drugs with new approval
  13. Charter's Rutledge, CBS's Moonves among highest-paid CEOs
  14. Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
  15. Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval
  16. Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
  17. Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
  18. Regeneron And Sanofi Have A Near-Term FDA Catalyst
  19. ETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 22, 2017